Darbepoetin alfa biosimilar JR-131 demonstrates equivalence in phase III study Jan. 18, 2018 No Comments
Endari now available in U.S. for sickle cell disease in adult and pediatric patients Jan. 18, 2018 No Comments
Bioverativ conducts phase III trials with BIVV-009 in primary cold agglutinin disease Jan. 17, 2018 No Comments
JTZ-951, a HIF-PH inhibitor, shows positive results for treating renal anemia Jan. 10, 2018 No Comments
Global Blood Therapeutics' voxelotor given breakthrough therapy designation for sickle cell disease Jan. 10, 2018 No Comments
Enrollment begins in phase II/III program for Catalyst Biosciences' marzeptacog alfa Jan. 5, 2018 No Comments
RSS